150 related articles for article (PubMed ID: 28101578)
1. A 22q11.2 amplification in the region encoding microRNA-650 correlates with the epithelial to mesenchymal transition in breast cancer primary cultures of Mexican patients.
Lango-Chavarría M; Chimal-Ramírez GK; Ruiz-Tachiquín ME; Espinoza-Sánchez NA; Suárez-Arriaga MC; Fuentes-Pananá EM
Int J Oncol; 2017 Feb; 50(2):432-440. PubMed ID: 28101578
[TBL] [Abstract][Full Text] [Related]
2. 53BP1 suppresses epithelial-mesenchymal transition by downregulating ZEB1 through microRNA-200b/429 in breast cancer.
Kong X; Ding X; Li X; Gao S; Yang Q
Cancer Sci; 2015 Aug; 106(8):982-9. PubMed ID: 26011542
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-9 is associated with epithelial-mesenchymal transition, breast cancer stem cell phenotype, and tumor progression in breast cancer.
Gwak JM; Kim HJ; Kim EJ; Chung YR; Yun S; Seo AN; Lee HJ; Park SY
Breast Cancer Res Treat; 2014 Aug; 147(1):39-49. PubMed ID: 25086633
[TBL] [Abstract][Full Text] [Related]
4. miR-671-5p inhibits epithelial-to-mesenchymal transition by downregulating FOXM1 expression in breast cancer.
Tan X; Fu Y; Chen L; Lee W; Lai Y; Rezaei K; Tabbara S; Latham P; Teal CB; Man YG; Siegel RS; Brem RF; Fu SW
Oncotarget; 2016 Jan; 7(1):293-307. PubMed ID: 26588055
[TBL] [Abstract][Full Text] [Related]
5. Dual regulation by microRNA-200b-3p and microRNA-200b-5p in the inhibition of epithelial-to-mesenchymal transition in triple-negative breast cancer.
Rhodes LV; Martin EC; Segar HC; Miller DF; Buechlein A; Rusch DB; Nephew KP; Burow ME; Collins-Burow BM
Oncotarget; 2015 Jun; 6(18):16638-52. PubMed ID: 26062653
[TBL] [Abstract][Full Text] [Related]
6. Epithelial-mesenchymal transition increases during the progression of in situ to invasive basal-like breast cancer.
Choi Y; Lee HJ; Jang MH; Gwak JM; Lee KS; Kim EJ; Kim HJ; Lee HE; Park SY
Hum Pathol; 2013 Nov; 44(11):2581-9. PubMed ID: 24055090
[TBL] [Abstract][Full Text] [Related]
7. The role of p53-microRNA 200-Moesin axis in invasion and drug resistance of breast cancer cells.
Alam F; Mezhal F; El Hasasna H; Nair VA; Aravind SR; Saber Ayad M; El-Serafi A; Abdel-Rahman WM
Tumour Biol; 2017 Sep; 39(9):1010428317714634. PubMed ID: 28933253
[TBL] [Abstract][Full Text] [Related]
8. Down-regulation of miR-129-5p via the Twist1-Snail feedback loop stimulates the epithelial-mesenchymal transition and is associated with poor prognosis in breast cancer.
Yu Y; Zhao Y; Sun XH; Ge J; Zhang B; Wang X; Cao XC
Oncotarget; 2015 Oct; 6(33):34423-36. PubMed ID: 26460733
[TBL] [Abstract][Full Text] [Related]
9. Expression of epithelial-mesenchymal transition-related markers in triple-negative breast cancer: ZEB1 as a potential biomarker for poor clinical outcome.
Jang MH; Kim HJ; Kim EJ; Chung YR; Park SY
Hum Pathol; 2015 Sep; 46(9):1267-74. PubMed ID: 26170011
[TBL] [Abstract][Full Text] [Related]
10. Loss of the polycomb protein Mel-18 enhances the epithelial-mesenchymal transition by ZEB1 and ZEB2 expression through the downregulation of miR-205 in breast cancer.
Lee JY; Park MK; Park JH; Lee HJ; Shin DH; Kang Y; Lee CH; Kong G
Oncogene; 2014 Mar; 33(10):1325-35. PubMed ID: 23474752
[TBL] [Abstract][Full Text] [Related]
11. MiR-153 inhibits epithelial-mesenchymal transition by targeting metadherin in human breast cancer.
Li W; Zhai L; Zhao C; Lv S
Breast Cancer Res Treat; 2015 Apr; 150(3):501-9. PubMed ID: 25794773
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of miR-153 contributes to epithelial-mesenchymal transition and tumor metastasis in human epithelial cancer.
Xu Q; Sun Q; Zhang J; Yu J; Chen W; Zhang Z
Carcinogenesis; 2013 Mar; 34(3):539-49. PubMed ID: 23188671
[TBL] [Abstract][Full Text] [Related]
13. Epithelial-to-mesenchymal transition (EMT) in intraductal papillary mucinous neoplasm (IPMN) is associated with high tumor grade and adverse outcomes.
Lahat G; Lubezky N; Loewenstein S; Nizri E; Gan S; Pasmanik-Chor M; Hayman L; Barazowsky E; Ben-Haim M; Klausner JM
Ann Surg Oncol; 2014 Dec; 21 Suppl 4():S750-7. PubMed ID: 25069861
[TBL] [Abstract][Full Text] [Related]
14. DNA methylation contributes to deregulation of 12 cancer-associated microRNAs and breast cancer progression.
Pronina IV; Loginov VI; Burdennyy AM; Fridman MV; Senchenko VN; Kazubskaya TP; Kushlinskii NE; Dmitriev AA; Braga EA
Gene; 2017 Mar; 604():1-8. PubMed ID: 27998789
[TBL] [Abstract][Full Text] [Related]
15. miR-381 inhibited breast cancer cells proliferation, epithelial-to-mesenchymal transition and metastasis by targeting CXCR4.
Xue Y; Xu W; Zhao W; Wang W; Zhang D; Wu P
Biomed Pharmacother; 2017 Feb; 86():426-433. PubMed ID: 28012397
[TBL] [Abstract][Full Text] [Related]
16. microRNA-203 suppresses invasion and epithelial-mesenchymal transition induction via targeting NUAK1 in head and neck cancer.
Obayashi M; Yoshida M; Tsunematsu T; Ogawa I; Sasahira T; Kuniyasu H; Imoto I; Abiko Y; Xu D; Fukunaga S; Tahara H; Kudo Y; Nagao T; Takata T
Oncotarget; 2016 Feb; 7(7):8223-39. PubMed ID: 26882562
[TBL] [Abstract][Full Text] [Related]
17. Breast cancer-associated fibroblasts induce epithelial-to-mesenchymal transition in breast cancer cells.
Soon PS; Kim E; Pon CK; Gill AJ; Moore K; Spillane AJ; Benn DE; Baxter RC
Endocr Relat Cancer; 2013 Feb; 20(1):1-12. PubMed ID: 23111755
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L
Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030
[TBL] [Abstract][Full Text] [Related]
19. Transcription factors associated with epithelial-mesenchymal transition and cancer stem cells in the tumor centre and margin of invasive breast cancer.
Alkatout I; Wiedermann M; Bauer M; Wenners A; Jonat W; Klapper W
Exp Mol Pathol; 2013 Feb; 94(1):168-73. PubMed ID: 22985790
[TBL] [Abstract][Full Text] [Related]
20. PIK3R1 targeting by miR-21 suppresses tumor cell migration and invasion by reducing PI3K/AKT signaling and reversing EMT, and predicts clinical outcome of breast cancer.
Yan LX; Liu YH; Xiang JW; Wu QN; Xu LB; Luo XL; Zhu XL; Liu C; Xu FP; Luo DL; Mei P; Xu J; Zhang KP; Chen J
Int J Oncol; 2016 Feb; 48(2):471-84. PubMed ID: 26676464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]